GammaCan Retains Investor Relations Firm ROI Group
June 27 2007 - 8:00AM
Business Wire
GammaCan International, Inc. (�GammaCan� or �the Company�) (OTCBB:
GCAN), a developer of proprietary immunotherapies for the treatment
of melanoma and other cancers, today announced it has retained
investor relations firm ROI Group. GammaCan develops proprietary
immunotherapy and related approaches to treat melanoma and other
cancers. GammaCan's platform patented technology is based on the
use of IgGs (gamma-immunoglobulins), a safe, relatively non-toxic
human plasma-derived product used to treat a variety of immune
deficiencies and autoimmune diseases. In cancer, IgG-based
therapies work by strengthening the patient's immune system. Many
experts currently view immunotherapy as a future alternative to
chemotherapy. The Company�s lead drug candidate, VitiGam�, targets
Stage lll and Stage lV melanoma for which no effective treatment
currently exists. In making the announcement, Steven Katz, Chairman
of the Board and President of GammaCan said, �In seeking to
establish GammaCan as a leader in developing novel immunotherapy
and related approaches to cancer, we are rapidly moving forward
with multiple strategic initiatives. VitiGam�, targeting Stage III
and Stage IV melanoma, is slated to enter Phase I/II human clinical
trials in early 2008.� �As we approach submitting an IND and
initiating clinical trials, it is now an appropriate time to
broaden our shareholder base by presenting GammaCan to retail and
institutional investors,� Mr. Katz continued. Robert Giordano, a
Managing Partner of ROI Group, commented on ROI�s appointment, �We
are very excited to work with GammaCan in communicating their
leading-edge IgG-based immunotherapy approach to treating various
cancers, particularly advanced stage melanoma.� �ROI has a track
record for delivering successful investor relations strategies
tailored to the requirements of small cap life science companies to
maximize shareholder value. We anticipate the same with GammaCan,�
said Mr. Giordano. About VitiGam� VitiGam� is a first-in-class
IgG-based anti-cancer immunotherapy being developed for the
treatment of Stage III and Stage IV melanoma. GammaCan is planning
to submit its Investigational New Drug Application (IND) for
VitiGam� to the FDA in the near future. The Company expects to
commence human clinical trials shortly thereafter. VitiGam� is an
IgG-based product manufactured from the plasma of donors with
Vitiligo, a benign skin condition affecting up to 2% of the general
population. Studies have shown that this "enriched" IgG formulation
contains potent anti-melanoma activity. Based on these studies,
GammaCan expects VitiGam� to provide both, specific anti-melanoma
activity (directed against melanoma cells), and non-specific
anti-cancer activity. About Melanoma Melanoma is a deadly form of
skin cancer. According to the American Cancer Society, melanoma
accounts for approximately 4% of all skin cancers but causes
approximately 75% of all skin cancer-related deaths. An estimated
62,000 people will be diagnosed with and nearly 8,000 people will
die from melanoma in the U.S. alone in 2007. If rapidly diagnosed
and surgically removed, early-stage melanoma is usually curable.
However, for patients with metastatic melanoma (Stage III and Stage
IV), the prognosis is poor since no effective treatment currently
exists. These patients have a median survival time of 8.5 months
and a 5-year survival rate of less than 10%. There has been little
change in these results for in excess of 25 years. The incidence of
melanoma has increased more rapidly than any other cancer during
the past 10 years. The last drug to treat patients with metastatic
melanoma was approved by the FDA over 30 years ago. For more
information about GammaCan, visit www.GammaCan.com. Safe Harbor
Statement Statements in this document that are not purely
historical are forward-looking statements. Forward-looking
statements in this release include statements regarding: the
commercialization of anti-cancer immunotherapies and the Company's
efforts to develop therapies to boost the immune systems of cancer
patients by the use of IgG-based therapy. Actual outcomes and the
Company's actual results could differ materially from those in such
forward-looking statements. Factors that could cause actual results
to differ materially include risks and uncertainties such as the
inability to finance the planned development of the technology, the
inability to hire appropriate staff to develop the technology,
unforeseen technical difficulties in developing the technology, the
inability to obtain regulatory approval for human use, competitors'
therapies proving to be more effective, cheaper or otherwise
preferable for consumers, the inability to market a product, all of
which could, among other things, delay or prevent product release,
as well as other factors expressed from time to time in GammaCan's
periodic filings with the Securities and Exchange Commission (the
"SEC"). As a result, this press release should be read in
conjunction with GammaCan's periodic filings with the SEC, which
are incorporated herein by reference. The forward-looking
statements contained herein are made only as of the date of this
press release and GammaCan undertakes no obligation to publicly
update such forward-looking statements to reflect subsequent events
or circumstances.
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2023 to Jul 2024